Delray Medical Center Becomes 1st Hospital in South Florida to Use Modus V™ 3D System for Brain & Spine Surgery

April 15, 2021

Delray Medical Center is the first hospital in South Florida to use the Synaptive’s Modus V™ 3D exoscope.

This technology is a fully automated, robotic digital microscope combining advanced optics with 3D visualization, video processing and robotic automation allowing for a more precise excision of brain tumors.

Delray Medical Center is also the first hospital in South Florida to use the Modus V™ 3D for spinal surgery.  Utilizing voice-control surgeons can maintain focus at all times on the surgical field.

“This new technology is designed to offer improved procedural outcomes for patients, and give us the best opportunity to safely operate on the brain and spine,” said Dr. Lloyd Zucker, medical director of neurosurgery for Delray Medical Center.  “We look forward to bringing these benefits to our patients at Delray Medical Center.  The hospital is committed to bringing this and other groundbreaking technologies to South Florida.”

Unlike traditional microscopes, Modus V allows all members of the operating room team to see the magnified surgical field in 3D, which is displayed on a screen.  At the same time the surgeon is viewing it in 3D.  The Modus V provides a larger depth of field and magnification than a conventional operating microscope.

The video exoscope provides the clinician with auto-focus and voice-activated controls.  This allows control of the camera position and all other camera functions hands-free, so the surgeon can keep operating at all times with better visualization and navigation.

“This advanced technology gives us a new option to treat patients with brain tumors, that could also enable them to have a better long-term quality of life,” said Maggie Gill, chief executive officer for the Palm Beach Health Network and Delray Medical Center. “We are always striving to bring patients in Palm Beach County the most comprehensive neurological treatment options close to home, and in a safe environment.” More Delray Medical Technology featured news.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”